Notably, the phase III KEYNOTE-048 trial demonstrated that pembrolizumab, an anti-PD-1 antibody, improved overall survival compared to standard chemotherapy in patients with PD-L1-positivel recurrent or metastatic HNSCC [41]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.